Q1 Earnings Forecast for enGene Issued By HC Wainwright

enGene Holdings Inc. (NASDAQ:ENGN) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of enGene in a research note issued on Friday, September 12th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.64) for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene’s Q2 2026 earnings at ($0.59) EPS and Q3 2026 earnings at ($0.63) EPS.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06).

Separately, Morgan Stanley lowered their target price on enGene from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.00.

enGene Stock Up 1.7%

Shares of NASDAQ:ENGN opened at $6.07 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.34 and a current ratio of 10.34. enGene has a 52-week low of $2.65 and a 52-week high of $11.00. The business’s 50 day simple moving average is $4.21 and its two-hundred day simple moving average is $4.12. The firm has a market cap of $310.18 million, a P/E ratio of -3.19 and a beta of -0.39.

Hedge Funds Weigh In On enGene

Several institutional investors have recently modified their holdings of ENGN. VR Adviser LLC lifted its holdings in enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after acquiring an additional 1,480,573 shares during the period. Toronto Dominion Bank bought a new stake in shares of enGene during the 4th quarter worth $97,000. Vestal Point Capital LP purchased a new position in shares of enGene in the 4th quarter worth about $2,460,000. Point72 Asset Management L.P. boosted its holdings in shares of enGene by 84.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after buying an additional 561,797 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in enGene by 2.7% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock valued at $7,041,000 after buying an additional 41,874 shares during the period. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.